Dexpramipexole dihydrochloride

Research use only, not for human use.

A partial/full agonist of dopamine receptor with Ki of 3.9/2.2/0.5/5.1 nM for D2S/D2L/D3/D4, respeectively.

A partial/full agonist of dopamine receptor with Ki of 3.9/2.2/0.5/5.1 nM for D2S/D2L/D3/D4, respeectively; also possesses low/insignificant affinity (500–10,000 nM) for the 5-HT1A, 5-HT1B, 5-HT1D, and α2-adrenergic receptors; used for treating Parkinson's disease (PD) and restless legs syndrome (RLS).Alzheimer's Disease Phase 2 Clinical(In Vitro):Dexpramipexole has been found to have neuroprotective effects and is being investigated for treatment of amyotrophic lateral sclerosis (ALS). Dexpramipexole reduces mitochondrial reactive oxygen species (ROS) production, inhibits the activation of apoptotic pathways, and increase cell survival in response to a variety of neurotoxins and β-amyloid neurotoxicity. Compared to the S-(-) isomer, Dexpramipexole has much lower dopamine agonist activity.

Dexpramipexole has been found to have neuroprotective effects and is being investigated for treatment of amyotrophic lateral sclerosis (ALS). Dexpramipexole reduces mitochondrial reactive oxygen species (ROS) production, inhibits the activation of apoptotic pathways, and increase cell survival in response to a variety of neurotoxins and β-amyloid neurotoxicity. Compared to the S-(-) isomer, Dexpramipexole has much lower dopamine agonist activity.

——

R)-Pramipexole | KNS-760704

GPCR/G Protein

Dopamine Receptor

Dopamine Receptor

Neurological Disease

Alzheimer Disease

104632-27-1

284.249

C10H19Cl2N3S

>98% (HPLC)

DMSO: ≥ 28 mg/mL

CCCNC1CCC2=C(C1)SC(=N2)N.Cl.Cl

2,6-Benzothiazolediamine, 4,5,6,7-tetrahydro-N6-propyl-, hydrochloride (1:2), (6R)-

(-20℃)

With Ice Pack

≥ 2 years